Drug intelligence / Profile preview

TH-407b

Development stage: Preclinical
Lead developer: Toll Biotech Co., Ltd.
Modality: Small Molecules

Overview

**TH-407b** is a potent and selective small molecule inhibitor of Toll-like receptor 7 (TLR7). It dose-dependently inhibits R848-induced TLR7 activation with an IC50 of 0.23 µM in HEK-Blue hTLR7 cells[1]. This molecule stabilizes TLR7 in its resting/inactivated state, thereby suppressing TLR7-mediated pro-inflammatory signaling. TH-407b demonstrates anti-inflammatory activity in cell cultures and peripheral blood mononuclear cells from systemic lupus erythematosus (SLE) patients, and shows efficacy in mouse models of SLE[4]. It is being developed by Toll Biotech Co.Ltd.(Beijing) for immune system diseases, with systemic lupus erythematosus as its primary indication[4]. The drug is in preclinical development[4].

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on TH-407b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TH-407b.

Explore the full profile